NKE vs PFE: Which Is the Better Buy?
Side-by-side comparison of NIKE, Inc. and Pfizer Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-05-05.
NIKE, Inc. · Consumer Cyclical
$42.62
+38.4% upside to fair value
Med Conviction
Grade B+
VS
Pfizer Inc. · Healthcare
$26.33
+28.6% upside to fair value
Grade B
QuantHub Verdict
NKE has more upside to fair value
(+38.4%).
PFE trades at a lower forward P/E
(19.3x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
NKE |
PFE |
| Current Price |
$42.62 |
$26.33 |
| Fair Value Estimate |
$58.98 |
$33.85 |
| Upside to Fair Value |
+38.4%
|
+28.6%
|
| Market Cap |
$63.0B |
$149.8B |
| Forward P/E |
27.9x
|
19.3x
|
| EV / EBITDA |
20.7x
|
12.9x
|
| Price / Sales |
1.4x
|
2.4x
|
| Price / FCF |
19.4x
|
16.5x
|
| Revenue Growth YoY |
-9.8%
|
-1.2%
|
| Gross Margin |
42.7%
|
70.3%
|
| Operating Margin |
8.0%
|
24.7%
|
| Return on Equity |
24.4%
|
8.7%
|
| Dividend Yield |
3.8% |
0% |
| FCF Yield |
5.2%
|
6.06%
|
| Analyst Consensus |
Buy
|
Hold
|
Investment Thesis
Nike is the world's largest athletic footwear and apparel company with $46.3B in FY2025 revenue, operating across 190+ countries with the Nike, Jordan, and Converse brands. The stock trades near its 9-year low at $42.62 after an 11% single-day crash following a Q3 FY2026 earnings report that showed 35% net income decline and weak Q4 guidance calling for a further 2-4% revenue decline. FY2025 reve…
Pfizer Inc. is a leading global pharmaceutical company specializing in drug manufacturing with a strong presence in vaccines, oncology, and primary care. The company benefits from a seasoned leadership team under CEO Albert Bourla, who has driven a strategic transformation focusing on science-driven innovation and portfolio optimization. Despite a high gross margin of 70.3% and solid operating ma…
Accumulation Zones
| Metric |
NKE |
PFE |
| Zone Low |
$44.23 |
$25.39 |
| Zone High |
$50.13 |
$28.77 |
| In Buy Zone? |
Yes
|
Yes
|